What is ALMS stock price today?

ALMS (Alumis Inc) stock is trading at $26.34 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALMS stock going up or down today?

ALMS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALMS stock now?

The decision to buy ALMS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALMS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALMS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALMS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ALMS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ALMS's P/E ratio?

P/E ratio data for ALMS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ALMS's market cap?

ALMS (Alumis Inc) has a market capitalization of $3.50 billion, making it a small-cap stock.

What is ALMS's price to book ratio?

ALMS trades at a price-to-book (P/B) ratio of 9.11, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ALMS pay dividends?

ALMS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALMS's dividend yield?

ALMS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALMS stock a good long-term investment?

ALMS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALMS's revenue growth rate?

Revenue growth data for ALMS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ALMS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ALMS?

Key risks for ALMS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALMS compare to its competitors?

Compare ALMS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALMS's performance and positioning.

What is ALMS's stock price target for 2026?

Our AI model provides price targets for ALMS based on fundamental analysis: Bull case $34.24 (+30%), Base case $30.29 (+15%), Bear case $23.71 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALMS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALMS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALMS's next earnings report?

ALMS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALMS - Alumis Inc

NYSE * Health Care * Biotechnology

$26.34

$-1.76 (-6.26%)

About Alumis Inc

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

ALMS Key Statistics

Market Cap

$3.50B

P/B Ratio

9.11

EPS

$-2.15

Employees

221

How ALMS Compares to Peers

ALMS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ALMS(This stock)	$3.50B	N/A	0%	0.0%	-
AMGNAmgen Inc	$202.38B	26.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$184.43B	21.9	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$126.79B	32.6	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$81.62B	18.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.95B	21.4	-0%	0.1%	vs BIIB

Alumis Inc Company Information

Headquarters: California; U.S.A
Website: www.alumis.com
Sector: Health Care
Industry: Biotechnology

Data Updated: March 12, 2026 at 5:11 PM EDT

Ready to invest in ALMS?

Commission-free trading available. Affiliate links.

ALMS Lician Score

5% confidence

4.0/10

Neutral

ALMS has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ALMSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ALMS Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ALMS

Dashboard

Enter a ticker to analyze